What Is Organ Transplantation?

Organ transplantation is the surgical procedure of transferring a functioning organ from a donor to a recipient whose own organ has failed or been removed due to disease, trauma, or congenital defect. It encompasses the transplantation of kidneys, livers, hearts, lungs, pancreases, intestines, and combinations of these organs, as well as composite tissue allografts such as hands and faces. The field integrates surgical technique, immunology, pharmacology, and biomedical engineering, with the central biological challenge being the recipient's immune system recognition of the transplanted organ as foreign and its subsequent rejection response.

Modern organ transplantation became clinically viable following the first successful kidney transplant between identical twins by Joseph Murray at Brigham Hospital in 1954 and the development of cyclosporine-based immunosuppression in the 1970s and 1980s, which substantially improved one-year graft survival rates. Despite these advances, long-term graft survival and the side effects of lifelong immunosuppressive therapy remain active areas of research.

Immunological Rejection

Rejection is the primary biological barrier to transplantation. When a recipient's immune system encounters the donor organ, it identifies the foreign major histocompatibility complex (MHC) antigens displayed on donor cells and mounts an inflammatory response. Hyperacute rejection occurs within minutes to hours through preformed antibodies; acute cellular rejection typically appears within days to weeks and is mediated by T lymphocytes; chronic rejection develops over months to years and is marked by fibrosis and vascular occlusion. The standard management is triple immunosuppression combining a calcineurin inhibitor such as tacrolimus, an antiproliferative agent, and corticosteroids. Research into immune tolerance induction strategies in organ transplantation aims to train the recipient's immune system to accept the donor organ without requiring lifelong drug therapy. A review on activation of immune signals during organ transplantation in Signal Transduction and Targeted Therapy describes the molecular pathways driving each rejection phase.

Organ Preservation and Allocation

Successful transplantation depends on maintaining organ viability from the moment of donor death to implantation in the recipient. Static cold storage in preservation solutions such as University of Wisconsin (UW) solution suppresses cellular metabolism at 4 degrees Celsius, typically allowing 12 to 24 hours of safe ischemic time for kidneys and 4 to 6 hours for hearts. Machine perfusion systems, including hypothermic machine perfusion (HMP) and normothermic machine perfusion (NMP), actively pump oxygenated solutions or blood through the organ, extending preservation times and allowing viability assessment before implantation. Organ allocation is governed by national registries (UNOS in the United States, Eurotransplant in Europe) that use scoring systems balancing medical urgency, compatibility, waiting time, and geography. The mismatch between organ supply and the roughly 100,000 patients on the U.S. waiting list at any given time drives research into expanded criteria donors, donation after circulatory death, and xenotransplantation.

Biomedical Engineering Contributions

Biomedical engineers contribute to organ transplantation through sensing, biomaterials, and computational modeling. Implantable scaffolds instrumented with biosensors allow early, minimally invasive detection of acute rejection before clinical symptoms appear; a University of Michigan BME study using scaffolding sensors demonstrated accumulation of immune cells in microporous implants as a rejection biomarker. Nanoparticle drug delivery systems under development aim to localize immunosuppression to the graft site rather than suppressing the entire systemic immune response. Computational immunobiology models the dynamics of T-cell activation and tolerance induction, informing dosing protocols and novel therapeutic targets. Bioartificial organs combining living cells with polymer scaffolds represent a longer-term engineering goal for renal and hepatic support.

Applications

Organ transplantation has applications in a wide range of fields, including:

• End-stage renal disease treatment through kidney transplantation
• Heart failure management via cardiac transplantation and bridging with ventricular assist devices
• Liver failure treatment including living-donor partial liver transplantation
• Type 1 diabetes management through pancreatic islet or whole pancreas transplantation
• Biomedical device development for organ preservation, graft monitoring, and tolerance induction